Role of Tumor Microenvironment in Breast Cancer and Targeted Therapies discusses the current understanding of breast cancer tumor microenvironment components, their role in tumorigenicity and the development of therapeutic resistance, along with updates on recent advances. - Presents up-to-date knowledge on the interplays of stromal components surrounding breast tumor cells - Explores recent advances and trends in the molecular mechanisms of breast tumorigenesis and how to explore further molecular targets

Cytokine and Chemokine Networks in Cancer" provides a comprehensive exploration of the roles of cytokines and chemokines in cancer biology. It offers valuable insights into their diagnostic, prognostic, and therapeutic implications, making it a valuable resource for researchers, clinicians, and students interested in the field of cancer immunology and therapy. This book illustrates the importance and significance of the cytokine and chemokine signaling networks in tumor development and progression. It describes the complex networks mediated by cytokine and chemokine receptors promoting tumor cell proliferation, site-directed metastasis, and activation of angiogenic switch in tumor cells. The books also shed light on the heterogeneity of cytokines and chemokine in solid malignancies and their impact on tumor progression and therapeutic outcomes. The chapters provide current information about the types of cytokine-chemokine interactions in promoting cancer stem cell-like characteristics, epithelial to mesenchymal transition, and modulation of the tumor microenvironment. The significance of the complex interactions in cancer biology in the light of therapeutic resistance is also highlighted. The chapters also describe recent advancements in the therapeutic potential of targeting the pro-tumor cytokine and chemokine networks and limiting tumor cell metastasis. Finally, the book also provides a comprehensive yet representative description of a large number of challenges associated with targeting these vital chemokine-cytokine networks. Given its content, the book provides valuable information for researchers in the field of cancer biology and molecular medicine.

This eBook consists of a collection of articles focused on fundamental processes of cancer cell metastasis, such as cell-Extracellular matrix adhesions, epithelial-to-mesenchymal transition (EMT) and lymph node metastasis as well as on upcoming research fields including the effects of biomechanical factors, the use of analytical and statistical tools and experimental techniques to further understand and characterize the invasive and metastatic potential of tumors.

This book reviews different aspects of the cancer microenvironment, and its regulation and importance for tumor progression. Methodological advancements and practical applications, in terms of how biomarkers are studied and increasingly included in clinical trials and therapy protocols, are described and discussed. Biomarkers of the Tumor Microenvironment is an educational resource for students and members of the cancer research community as a whole, especially for those using morphology analysis techniques and models focusing on the cross-talk between different cell types in tumors. The textbook provides a comprehensive overview of the microenvironment in various contexts from the perspectives of experienced and accomplished cancer researchers and clinicians.

Cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) therapy, has revolutionized the paradigm in cancer treatment. However, the clinical outcome of immunotherapy varies considerably among patients and only a minority of patients achieve long-term clinical benefits. This is largely attributed to the fact that existing cancer immunotherapies, which concentrate on several classical targets (CTAL-4, PD-1/PD-L1, etc.) and limited types of immune cell populations (T cells), are insufficient to cope with the complexity of highly heterogeneous tumor microenvironment (TME). This calls for more efforts to not only expand our toolbox for manipulating anticancer immunity but also diversify our combinational strategies. To this end, it is urgent to deeper our understanding of cancer immunotherapy by using both experimental and computational methodologies from multi-scale perspectives: 1) novel targets from either tumor cells or non-tumor cells within TME (e.g., tumor intrinsic resistance drivers, new immune checkpoints, neoantigens), 2) in-depth characterization of more immune cell populations (e.g., macrophages, Tregs, B cells) and their interactions and dynamics within TME, 3) landscape of actionable targets in patient populations for combination design. These efforts will open the avenue of rational design of combinational immunotherapies, allowing researchers and clinicians to design novel targeting therapeutics or to optimally orchestrate combinatory strategies aiming to surmount resistance mechanisms and improve clinical outcomes.